

SIRION Biotech to present insights on single cell level gene delivery to ASGCT 25th Anniversary Meeting

Graefelfing, Germany: - Viral technology specialist SIRION Biotech will be a high profile presence at the influential American Society of Gene and Cell Therapy (ASGCT) annual meeting, celebrating its 25th Anniversary in 2022.

SIRION has consistently attended ASGCT annual meetings over many years and has frequently contributed scientific insights to the Tools & Technology conference track.

Single cell gene delivery

This year will be no exception, with SIRION CEO Dr. Christian Thirion presenting the Tools & Technology talk 'Taking gene delivery to the single cell level' during the Day Two afternoon session (Tuesday, May 17, 16:15-16:30 hrs.).

Dr. Thirion's presentation will highlight the possibilities that stem from analysis of transduction profiles with single nuclei RNA sequencing and targeting individual cell types using nanobody retargeted AAV vectors.

USP development of recombinant AAVs for ocular applications

In addition, SIRION will contribute a Poster presentation (Tu-252, Final abstract number: 747) on 'Upstream Manufacturing Process Development of Recombinant AAV Vectors for Ocular Applications'. This will be delivered by AV Platform Manager Dr. Helena Meyer-Berg, during the Vector Product Engineering, Development or Manufacturing II Session in Hall D, A also on the afternoon of Day Two (Tuesday May 17, 17:30-18:30 hrs).

Exhibition stand

SIRION will also be an exhibitor at the ASGCT meeting, with a stand at Booth 218 at the Walter E. Washington Center.

"We have been supporting this event for many years. It provide us with one of the best opportunities of the year to share knowledge and to meet partners, and potential partners," said Dr. Carl Christel, SIRION VP for US Operations, who will also join the event team in Washington DC.

About SIRION Biotech

SIRION Biotech was founded in 2005 with the goal to spark a new generation of viral vector technologies for gene and cell therapy as well as vaccine development.

SIRION evolves novel therapeutic viral vectors and uses proprietary technology platforms based on lenti-, adeno-, and adeno-associated viruses, to expedite its partners' advances in drug development.

To date SIRION has completed over 8000 projects of all sizes, working closely with over 600 independent customer groups from academia and industry.

On August 31, 2021, SIRION was 100% acquired by PerkinElmer.

For additional information, please visit www.sirion-biotech.com.

About ASGCT 2022

The Wisconsin-based American Society of Gene and Cell Therapy (ASGCT) promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating

education, the exchange of information and technology, and by serving as a professional adviser to stakeholder communities and regulatory bodies across the Americas.

The ASGCT Annual Meeting, celebrating its 25th Anniversary in 2022, has become a premier event for professionals in gene and cell therapy.

The 2022 ASGCT Meeting is a four-day event, opening May 16 at the Walter E. Washington Convention Center in Mt. Vernon, Washington, D.C. The conference includes pre-event workshops, a co-located exhibition and Awards ceremony.

The event is organized by ASGCT with further information at: <https://annualmeeting.asgct.org>

